Corporate GovernanceApr 28, 2026, 04:27 PM
MDGL Board Reclassifies Directors Baker & Brennan to Class I
AI Summary
Madrigal Pharmaceuticals' Board of Directors reclassified the membership of its three director classes on April 22, 2026, to achieve a more equal apportionment. Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, effective immediately. This procedural change did not interrupt their service or alter their committee assignments, and they are nominated for re-election at the upcoming 2026 Annual Meeting.
Key Highlights
- MDGL Board reclassified directors to achieve more equal apportionment among the three classes.
- Julian C. Baker reclassified from Class III to Class I director.
- Daniel J. Brennan reclassified from Class II to Class I director.
- Reclassification was effective April 22, 2026.
- Service of Mr. Baker and Mr. Brennan on the Board is deemed to have continued uninterrupted.
- No changes to committee assignments for Mr. Baker or Mr. Brennan.
- Mr. Baker, Mr. Brennan, and James Daly nominated for re-election at the 2026 Annual Meeting.
Price Impact
More from MDGL